Feasibility of the Combination of Venetoclax and Asparaginase-based Chemotherapy for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Survival of adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal as they are often resistant to multiple salvage chemotherapy regimens. The recent approvals of novel agents, including the bispecific T-cell engager blinatumomab, the antibody-drug conjugate inotuzumab ozogamicin, and chimeric antigen receptor T-cell products, are changing the landscape of B-cell (B)-ALL, but little progress has been made in R/R T-cell (T)-ALL.1-4 Allogenic stem cell transplantation (allo-SCT) is the only potentially curative option but requires achievement of complete remission (CR) before transplant.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Jean El-Cheikh, Nour M. Moukalled, Haidar El Darsa, Radwan Massoud, Souha S. Kanj, Rami Mahfouz, Ali Bazarbachi Tags: Case Report Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants